New Mercies: Ria Bos - Mercy Ships
In this episode, Ria shares how Mercy Ships finds patients for surgery, the hope that is offered each person, and a night she’ll never forget.
Source: mercyships.org
📰 Patient Selection News
Page 2 - Patient Selection News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Patient Selection. Real-time updates on events, politics, business and more.
Finding Light in the Darkness - Mercy Ships
Umu's birth came with an unexpected twist as she entered the world with a benign tumor growing from the side of her face and neck.
Source: mercyships.org
Late-breaking Data Show Esprit BTK Drug-eluting Resorbable Scaffold Reduces Chronic Limb-threatening Ischemia Progression Compared to the Standard of Care
Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty
Source: dicardiology.com
Peptide Receptor Radionuclide Therapy (PRRT) Industry Set to Surge to US$1.3 Billion by 2033 at an I
The Peptide Receptor Radionuclide Therapy (PRRT) Industry is on a trajectory of exceptional growth, with projections indicating a worth of US$ 591.83 million in 2023 and a substantial leap towards US$ 1,300 million by 2033. This robust expansion is driven by a promising Compound Annual Growth Rate (CAGR) of 8.2% exp...
United States New York Market Insights Inc European Commission Consumer Technology Drug Administration
Source: pharmiweb.com
CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023
- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-k...
United States Emiliano Calvo Swethajit Biswas Globe Newswire Inc Cancer Genome Atlas Senior Investigator
Source: yahoo.com
Artificial Intelligence (AI) In Clinical Trials Market
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032...
City Of United Kingdom United States Vineti Inc Artificial Intelligence Services Global Market Nference Inc
Source: globenewswire.com
Mixed, 'Intriguing' Result for Stroke Neuroprotective Agent
Two new studies of the potential neuroprotective agent nerinetide for patients with acute ischemic stroke have shown conflicting results, with suggestions of benefit when given very early in the prehospital setting.
Source: medscape.com
Relapsed/Refractory Follicular Lymphoma: EZH2- and PIK3-Targeted Therapies
A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.
Treatment Approach Expanding Treatment Options Refractory Follicular Lymphoma Follicular Lymphoma Relapsed Refractory Fl Relapsed Refractory Follicular Lymphoma
Source: onclive.com
HUTCHMED Highlights Presentation of Results from the Phase
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today...
Source: globenewswire.com
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 -- HUTCHMED Limited ; class=js-l-obf link link--blue
Source: marketscreener.com